Synlogic (SYBX) Reports Q3 Loss of $0.43, Revenues Beat

Synlogic (NASDAQ: SYBX) reported Q3 EPS of ($0.43), versus $0.00 reported last year. Revenue for the quarter came in at $1.8 million versus the consensus estimate of $200 thousand.

“This is an exciting time for Synlogic, as we continue to explore the breadth of our platform. We have advanced SYNB1891, our dual innate immune activator for the treatment of cancer into IND-enabling studies,” said Aoife Brennan, M.B., B.Ch., Synlogic’s president and chief executive officer. “Our two orally administered Synthetic Biotic medicines, SYNB1618 for the treatment of phenylketonuria and SYNB1020 for the treatment of hyperammonemia, have demonstrated proof of mechanism in healthy volunteers and we look forward to clinical data from the ongoing clinical trials in patients in 2019.”

For earnings history and earnings-related data on Synlogic (SYBX) click here.

You May Also Be Interested In

• Mobileye (MBLY) misses estimates for Q1 earnings, revenue; shares slip
• Caterpillar (CAT) tops earnings expectations but sales volume declines
• International Paper Company (IP) Misses Q1 EPS by 5c